
    
      Primary Objective: To determine the safety and tolerability of single and multiple oral doses
      of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD).

      Secondary Objectives: To determine the single and multiple oral dose pharmacokinetics of SMT
      C1100 and its metabolites in patients with DMD.
    
  